- Active not recruitingPHASE2, PHASE3
Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
This study looks at a medicine called amlitelimab for moderate to severe eczema in people who've already tried it in other studies. We want to see how safe and effective it is over a long time, and if it continues to help.
For: Dermatitis AtopicUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
This study is testing a new medicine, Amlitelimab, for moderate-to-severe eczema in people aged 12 and over. It's looking at how well different doses work and if they're safe, compared to stopping treatment.
For: Dermatitis AtopicUnited States · Argentina · Australia - Active not recruitingPHASE2
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata
This study is looking into a new medicine called amlitelimab for people with severe alopecia areata. It wants to see if the medicine is safe and helps hair grow back. Some people will get the medicine, others a dummy treatment, to compare the results.
For: Alopecia AreataUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
This study looks at a new medicine called amlitelimab for people aged 12 and over with moderate-to-severe eczema. These individuals haven't responded well to other common eczema treatments. Researchers want to see if amlitelimab is safe and helps improve their skin when used with their usual steroid creams.
For: Dermatitis AtopicUnited States · Argentina · Australia - Active not recruitingPHASE2
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
This study looks at the long-term safety and effectiveness of a drug called amlitelimab for adults with moderate to severe asthma who have used it in a previous study. It will last up to 156 weeks.
For: AsthmaUnited States · Argentina · Brazil - Active not recruitingPHASE2
A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease
This study is testing a new medicine, amlitelimab, for adults with coeliac disease that isn't getting better with a gluten-free diet. It looks at how well the medicine works and if it's safe, by checking changes in the gut and how people feel.
For: Coeliac Disease · Celiac DiseaseUnited States · Argentina · Australia - Active not recruitingPHASE2
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
This study looks at a new treatment called amlitelimab for moderate to severe eczema in people aged 12 and older. It aims to understand its safety and how well it works over a long time. It involves regular visits and lasts several years.
For: Dermatitis AtopicUnited States · Argentina · Australia